Clinical outcomes of lung adenocarcinoma patients harboring uncommon epidermal growth factor receptor (EGFR) mutations treated with EGFR-tyrosine kinase inhibitors (TKIs)
Details
The content you want is available to Zendy users.Already have an account? Click here. to sign in.